Compare BridgeBio Pharma Inc (BBIO) vs Fiverr International Ltd (FVRR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Fiverr International Ltd — how do they compare? BridgeBio Pharma Inc trades at $82.87 (market cap $16.46B), while Fiverr International Ltd trades at $11.3 (market cap $397.97M). The key difference: BridgeBio Pharma Inc is far larger — about 41.4× Fiverr International Ltd's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Fiverr International Ltd nearer its low. Which is the better fit depends on your goals.
| BBIO | FVRR | |
|---|---|---|
Market Cap | $16.46B | $397.97M |
Sector | Health | Industrials |
52-Week High | $90.17 | $26.67 |
52-Week Low | $44.81 | $9.62 |
Enterprise Value | $18.02B | $128.57M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
Fiverr International (FVRR) trades at $11.27, up 2.08% today, with a bullish technical signal from moving averages. Revenue grew to $430.91M in 2025, with net income reaching $20.98M and a 4.86% margin. The stock appears undervalued with a P/E of 14.64 and P/S of 0.97. Recent news highlights Fiverr's upcoming Q2 2026 earnings and a surge in demand for AI coding specialists, though the stock remains near its 52-week low, down 66% from its high.
The outlook is mixed: strong profitability metrics and low valuation ratios present a potential opportunity, but risks include declining active buyers, ongoing legal investigations, and volatile cash flows. Analyst consensus leans neutral with 41% buy ratings, suggesting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →
